A new research has found that antibodies that protect against H7N9 avian flu have been isolated in individuals who received seasonal flu vaccinations.
The research conducted by University Of Chicago Medical Center explained that antibodies protection, which emerged in China account for a small percentage of the total immune response, but appear to neutralize H7 viruses and represent promising new targets for therapeutic development against a wide range of influenza strains.
Patrick Wilson, co-senior author said that the normal immune response to flu vaccination offers protection against dangerous and highly unique strains of influenza such as H7N9, so they will now develop ways of amplifying this response.
Carole Henry, author of the study said that they observed that antibodies induced by flu vaccination offer cross-protection against H7N9, although they are not always protective, H7-reactive antibodies can be found in almost everyone that's been vaccinated.
Wilson concluded that they will exploit this response on a larger scale to make vaccines or therapeutics that offer broad protection against influenza strains.
The study is published in the journal of Clinical Investigation.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
